Anti-CD19/CD3 Tetravalent Antibody AFM11

Known as: AFM11 
An anti-CD19/anti-CD3 bispecific tetravalent antibody with potential immunostimulatory and antineoplastic activities. Anti-CD19/CD3 tetravalent… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1964-2017
0246819642017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
To harness the potent tumor-killing capacity of T cells for the treatment of CD19(+) malignancies, we constructed AFM11, a… (More)
Is this relevant?
2015
2015
Significant interest in 44Sc as a radioactive synthon to label small molecules for positron emission tomography (PET) imaging has… (More)
Is this relevant?
2015
2015
The bottom-up assembly of nanoparticles into diverse ordered solids is a challenge because it requires nanoparticles, which are… (More)
  • figure 2
  • figure 1
  • figure 3
  • figure 4
  • figure 6
Is this relevant?
2014
2014
UNLABELLED Several ChimeriVax-Dengue (CYD)-based vaccination strategies were investigated as potential alternatives to… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2008
2008
Three independent, phase 1 clinical trials were conducted in Australia and in USA to assess the safety and immunogenicity of… (More)
  • figure 1
  • table 3
  • table 4
Is this relevant?
2008
2008
Patients with glioblastoma usually have a very poor prognosis. Even with a combination of radiotherapy plus temozolomide, the… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2006
2006
The efficacy of radioimmunotherapy (RIT) for patients with relapsed non-Hodgkin lymphoma (NHL) is limited by nonspecific delivery… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2004
Highly Cited
2004
BACKGROUND Control of meningococcal infection has a high priority in many industrialized nations, because of the high mortality… (More)
Is this relevant?
2004
2004
To develop an effective antitumor immunotherapy for B-lineage non-Hodgkin's lymphoma, we constructed a tetravalent tandem diabody… (More)
Is this relevant?
2003
2003
The clinical development of bispecific antibodies (BsAb) as therapeutics has been hampered by the difficulty in preparing the… (More)
Is this relevant?